Adjuvant therapy

MammaPrint and BluePrint as prognostic indicators for elderly patients with early-stage breast cancer

PUBLICATION: SABCS 2020 AUTHORS: Peter W. Blumencranz, Mehran Habibi, Read More

2024-03-25T08:05:58-07:00December 29th, 2020|Adjuvant, Evidence, MINT, Neoadjuvant|

Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial

PUBLICATION: European Journal of Cancer AUTHORS: Valesca P. Retel, Read More

2024-03-25T11:21:54-07:00September 1st, 2020|Adjuvant, Evidence, Healthcare Economics, MINDACT, Other|

Controlling Technical Variation Amongst 6693 Patient Microarrays of the Randomized MINDACT Trial

PUBLICATION: Communications Biology AUTHORS: Laurent Jacob, Anke Witteveen, Inès Beumer, Read More

2024-03-25T08:12:28-07:00July 27th, 2020|Adjuvant, Evidence, MINDACT|

Prospective Validation of a Genomic Assay in Breast Cancer: The 70-Gene MammaPrint Assay and the MINDACT Trial

PUBLICATION: Acta Medica Academica. Volume 48 (2) August 2019 AUTHOR: Read More

2024-03-25T08:46:25-07:00August 2nd, 2019|Adjuvant, Evidence, MammaPrint, MINDACT, Other, Validation|

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline

PUBLICATION: Journal of Clinical Oncology 37, no. 22 (August 01, Read More

2024-03-25T08:47:41-07:00August 1st, 2019|Adjuvant, Evidence, MINDACT|

The Changing Role of Gene-Expression Profiling in the Era of Deescalating Adjuvant Chemotherapy in Early-Stage Breast Cancer

PUBLICATION: Ann Surg Oncol (2019) 26: 3495. https://doi.org/10.1245/s10434-019-07511-8. AUTHORS: J.E.C. Read More

2024-03-25T08:50:09-07:00June 17th, 2019|Adjuvant, Evidence|
Go to Top